Institution
Innlandet Hospital Trust
Healthcare•Brumunddal, Norway•
About: Innlandet Hospital Trust is a healthcare organization based out in Brumunddal, Norway. It is known for research contribution in the topics: Population & Dementia. The organization has 387 authors who have published 1302 publications receiving 37753 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In a systematic review and meta‐analysis, celiac disease is found to be reported worldwide and there is a need for population‐based prevalence studies in many countries.
782 citations
••
TL;DR: The aim of this work was to identify potential correlations between human fecal microbiota (as a proxy for gut microbiota) and depression.
Abstract: Background
Depression is a chronic syndrome with a pathogenesis linked to various genetic, biological, and environmental factors. Several links between gut microbiota and depression have been established in animal models. In humans, however, few correlations have yet been demonstrated. The aim of our work was therefore to identify potential correlations between human fecal microbiota (as a proxy for gut microbiota) and depression.
Methods
We analyzed fecal samples from 55 people, 37 patients, and 18 non-depressed controls. Our analyses were based on data generated by Illumina deep sequencing of 16S rRNA gene amplicons.
Key Results
We found several correlations between depression and fecal microbiota. The correlations, however, showed opposite directions even for closely related Operational Taxonomic Units (OTU's), but were still associated with certain higher order phylogroups. The order Bacteroidales showed an overrepresentation (p = 0.05), while the family Lachnospiraceae showed an underrepresentation (p = 0.02) of OTU's associated with depression. At low taxonomic levels, there was one clade consisting of five OTU's within the genus Oscillibacter, and one clade within Alistipes (consisting of four OTU's) that showed a significant association with depression (p = 0.03 and 0.01, respectively).
Conclusions & Inferences
The Oscillibacter type strain has valeric acid as its main metabolic end product, a homolog of neurotransmitter GABA, while Alistipes has previously been shown to be associated with induced stress in mice. In conclusion, the taxonomic correlations detected here may therefore correspond to mechanistic models.
734 citations
••
Innlandet Hospital Trust1, University of Giessen2, University of Zaragoza3, Hedmark University College4, Université libre de Bruxelles5, University of Copenhagen6, University of Szeged7, University of Padua8, Leiden University9, University of Oslo10, Stavanger University Hospital11, Wrocław Medical University12, Cardiff University13
TL;DR: The association with depression and anxiety was highest for patients with psoriasis, atopic dermatitis, hand eczema, and leg ulcers, and only patients with Psoriasis had significant association with suicidal ideation.
558 citations
••
McMaster University1, Universidade Federal do Rio Grande do Sul2, University Health Network3, Alberta Health Services4, University of Lausanne5, North Shore-LIJ Health System6, Dalhousie University7, Royal Children's Hospital8, Ottawa Hospital Research Institute9, York University10, University of London11, Innlandet Hospital Trust12, Bond University13
TL;DR: This article covers studies answering questions about the prognosis of a typical patient from a broadly defined population and considers how to establish degree of confidence in estimates from such bodies of evidence.
Abstract: Introduction The term prognosis refers to the likelihood of future health outcomes in people with a given disease or health condition or with particular characteristics such as age, sex, or genetic profile. Patients and healthcare providers may be interested in prognosis for several reasons, so prognostic studies may have a variety of purposes,1–4 including establishing typical prognosis in a broad population, establishing the effect of patients’ characteristics on prognosis, and developing a prognostic model (often referred to as a clinical prediction rule) (Table 1). Considerations in determining the trustworthiness of estimates of prognosis arising from these types of studies differ. This article covers studies answering questions about the prognosis of a typical patient from a broadly defined population; we will consider prognostic studies assessing risk factors and clinical prediction guides in subsequent papers. Knowing the likely course of their disease may help patients to come to terms with, and plan for, the future. Knowledge of the risk of adverse outcomes or the likelihood of spontaneous resolution of symptoms is critical in predicting the likely effect of treatment and planning diagnostic investigations.5 If the probability of facing an adverse outcome is very low or the spontaneous remission of the disease is high (“good prognosis”), the possible absolute benefits of treatment will inevitably be low and serious adverse effects related to treatment or invasive diagnostic tests, even if rare, will loom large in any decision. If instead the probability of an adverse outcome is high (“bad prognosis”), the impact of new diagnostic information or of effective treatment may be large and patients may be ready to accept higher risks of diagnostic investigation and treatment related adverse effects. Inquiry into the credibility or trustworthiness of prognostic estimates has, to date, largely focused on individual studies of prognosis. Systematic reviews of the highest quality evidence including all the prognostic studies assessing a particular clinical situation are, however, gaining increasing attention, including the Cochrane Collaboration’s work (in progress) to define a template for reviews of prognostic studies (http://prognosismethods.cochrane.org/scope-ourwork). Trustworthy systematic reviews will not only ensure comprehensive collection, summarization, and critique of the primary studies but will also conduct optimal analyses. Matters that warrant consideration in such analyses include the method used to pool rates and whether analyses account for all the relevant covariates; the literature provides guidance on both questions.6 7 In this article, we consider how to establish degree of confidence in estimates from such bodies of evidence. The guidance in this article is directed primarily at researchers conducting systematic reviews of prognostic studies. It will also be useful to anyone interested in prognostic estimates and their associated confidence (including guideline developers) when evaluating a body of evidence (for example, a guideline panel using baseline risk estimates to estimate the absolute effect of Summary poIntS
472 citations
••
TL;DR: This guideline focuses on long-term administration of antithrombotic drugs designed for primary and secondary prevention of cardiovascular disease, including two new antiplatelet therapies.
432 citations
Authors
Showing all 390 results
Name | H-index | Papers | Citations |
---|---|---|---|
Bjørn Moum | 60 | 220 | 12824 |
Knut Engedal | 59 | 398 | 14223 |
Per Olav Vandvik | 54 | 221 | 12488 |
Trond Markestad | 54 | 216 | 9846 |
Per Andersen | 52 | 142 | 13964 |
Jan Aaseth | 45 | 230 | 6286 |
Geir Selbæk | 42 | 249 | 10334 |
Ola E. Dahl | 41 | 105 | 13117 |
Martin A. Walter | 38 | 111 | 5835 |
Tor A. Strand | 37 | 203 | 5598 |
Marit S. Jordhøy | 35 | 64 | 3712 |
Lars Lien | 35 | 168 | 4103 |
Jørgen G. Bramness | 32 | 215 | 3965 |
Bettina S. Husebo | 32 | 120 | 3563 |
Jūratė Šaltytė Benth | 32 | 149 | 3667 |